Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

11.36 

0.13 1.2%

as of Mar 05 '21

52 Week Range:

4.81 19.43


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Equity (BVPS) 1.23
1.60
1.22
2.03
3.04
2.89
2.03
2.18
3.72
3.61
3.67
growth rate 30.1% -23.8% 66.4% 49.8% -4.9% -29.8% 7.4% 70.6% -3.0% 1.7%
Earnings BIT -24.85
-35.75
-22.26
-26.62
-26.55
-46.79
-68.46
-56.36
-77.15
-105.18
-129.55
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE -8.60
-7.90
-12.00
-5.07
-5.07
-5.07
-5.07
-15.31
-15.31
-15.31
-15.31
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROA -33.04
-47.56
-26.21
-23.84
-13.76
-17.68
-38.20
-24.55
-15.58
-15.50
-15.35
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE -38.93
-52.56
-30.70
-28.54
-16.09
-20.40
-43.61
-33.67
-24.65
-23.82
-26.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC -38.93
-52.63
-30.70
-28.54
-16.09
-20.40
-42.59
-30.94
-22.52
-21.77
-25.05
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 8.65
11.90
7.78
9.60
9.14
10.58
11.25
5.54
5.23
5.80
4.60
growth rate 37.6% -34.6% 23.4% -4.8% 15.8% 6.3% -50.8% -5.6% 10.9% -20.7%
Quick Ratio 8.60
11.85
7.72
9.51
9.09
10.54
11.12
5.50
5.16
5.73
4.51
growth rate 37.8% -34.9% 23.2% -4.4% 16.0% 5.5% -50.5% -6.2% 11.1% -21.3%
Leverage 1.13
1.09
1.27
1.16
1.18
1.13
1.16
1.53
1.61
1.47
1.88
growth rate -3.5% 16.5% -8.7% 1.7% -4.2% 2.7% 31.9% 5.2% -8.7% 27.9%
Balance Sheet Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Acct.Receivable 0.40
1.25
4.32
3.49
10.79
2.83
5.20
3.58
5.05
37.59
6.26
growth rate 212.5% 245.5% -19.1% 208.9% -73.8% 83.7% -31.0% 40.9% 644.7% -83.4%
Acct.Payable 7.19
6.49
7.57
5.53
3.91
2.58
0.02
3.36
6.67
12.55
growth rate -9.8% 16.8% -27.1% -29.3% -33.9% -99.4% 20,868.8% 98.8% 88.2%
Cur.Assets 61.30
85.69
68.37
97.27
190.88
212.58
149.58
248.40
410.52
405.47
659.67
growth rate 39.8% -20.2% 42.3% 96.2% 11.4% -29.6% 66.1% 65.3% -1.2% 62.7%
Total Assets 63.00
87.34
82.53
140.84
243.21
217.24
157.89
286.74
590.40
637.52
938.55
growth rate 38.6% -5.5% 70.6% 72.7% -10.7% -27.3% 81.6% 105.9% 8.0% 47.2%
Cash 10.80
16.77
21.68
10.51
6.03
69.48
22.06
49.83
140.42
80.43
131.33
growth rate 55.2% 29.3% -51.5% -42.6% 1,052.3% -68.3% 125.9% 181.8% -42.7% 63.3%
Inventory 0.00 0.00 0.00
growth rate
Cur.Liabilities 7.10
7.20
8.79
10.13
20.88
20.10
13.29
44.86
78.51
69.87
143.55
growth rate 1.5% 22.0% 15.3% 106.1% -3.8% -33.9% 237.5% 75.0% -11.0% 105.4%
Liabilities 7.10
7.20
17.64
19.13
36.58
24.80
21.70
98.84
223.14
204.78
441.18
growth rate 1.5% 144.8% 8.5% 91.2% -32.2% -12.5% 355.6% 125.8% -8.2% 115.5%
LT Debt 0.00
0.00
0.00
3.95
3.95
3.95
24.74
growth rate 0.0% 0.0% 527.1%
Equity 55.90
80.13
64.90
121.71
206.63
192.44
136.20
187.90
366.52
432.55
498.23
growth rate 43.4% -19.0% 87.6% 69.8% -6.9% -29.2% 38.0% 95.1% 18.0% 15.2%
Common Shares 45.00
51.00
53.00
56.00
67.00
70.00
71.00
78.00
97.00
112.00
134.00
growth rate 13.3% 3.9% 5.7% 19.6% 4.5% 1.4% 9.9% 24.4% 15.5% 19.6%
Cash Flow Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Capital Expenditures 0.70
0.58
0.72
0.43
0.73
0.73
0.73
3.75
43.07
20.68
14.71
growth rate -17.7% 25.5% -40.3% 69.4% 0.0% 0.0% 412.4% 1,048.1% -52.0% -28.8%
Cash Dividends 0.00 0.00 0.00
growth rate
Cash From OA -23.93
-25.90
0.00
-5.68
-33.72
-65.88
11.18
36.55
-144.40
169.88
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% 227.0% -100.0% 100.0%
FCF per Share -0.55
-0.59
-0.17
-0.34
-0.08
-0.43
-0.90
0.18
0.47
-1.89
1.06
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 161.1% -100.0% 100.0%
Sale Purchase of Stock 51.92
1.68
78.12
106.73
21.26
1.11
98.14
growth rate -96.8% 4,561.2% 36.6% -80.1% -94.8% 8,718.0%
FCF -25.00
-26.00
-9.00
-20.00
-6.00
-36.00
-67.00
7.00
-6.00
-165.00
155.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0% 100.0%
Income Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Sales 20.80
10.32
21.66
24.13
45.87
39.54
19.39
36.57
84.45
102.43
118.19
growth rate -50.4% 109.9% 11.4% 90.1% -13.8% -51.0% 88.6% 131.0% 21.3% 15.4%
Op.Income -24.90
-35.75
-22.26
-26.62
-26.55
-46.79
-68.46
-56.36
-77.15
-105.18
-129.55
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT 0.00
-35.75
-22.26
-26.62
-26.42
-46.43
-71.67
-54.57
-68.89
-95.42
-120.78
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income -24.90
-35.75
-22.26
-26.62
-26.42
-40.70
-71.66
-54.57
-68.33
-95.19
-121.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS -0.55
-0.71
-0.42
-0.48
-0.39
-0.58
-1.02
-0.70
-0.70
-0.85
-0.90
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 20.80
10.32
21.66
24.13
-10.87
-27.59
-46.23
-29.16
-30.41
-43.49
-62.46
growth rate -50.4% 109.9% 11.4% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
R&D 33.20
32.10
31.71
37.04
56.97
114.87
114.87
114.87
114.87
145.92
-180.65
growth rate -3.3% -1.2% 16.8% 53.8% 101.6% 0.0% 0.0% 0.0% 27.0% -100.0%

Quarterly Statements

Item Name Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Earnings BIT 1.47
-44.52
-37.90
-3.70
-43.43
growth rate -100.0% 0.0% 0.0% 0.0%
Balance Sheet Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Acct.Receivable 37.59
7.90
6.15
40.31
6.26
growth rate -79.0% -22.1% 555.2% -84.5%
Acct.Payable 6.67
13.62
15.85
14.46
12.55
growth rate 104.2% 16.3% -8.8% -13.2%
Cur.Assets 405.47
370.95
679.40
700.29
659.67
growth rate -8.5% 83.2% 3.1% -5.8%
Total Assets 637.52
584.28
894.66
963.71
938.55
growth rate -8.4% 53.1% 7.7% -2.6%
Cash 80.43
85.75
467.44
259.39
131.33
growth rate 6.6% 445.1% -44.5% -49.4%
Inventory
growth rate
Cur.Liabilities 69.87
62.07
93.94
123.56
143.55
growth rate -11.2% 51.4% 31.5% 16.2%
Liabilities 204.78
189.86
383.45
442.83
441.18
growth rate -7.3% 102.0% 15.5% -0.4%
LT Debt 40.20
growth rate
Equity 432.55
394.29
511.46
521.41
498.23
growth rate -8.9% 29.7% 2.0% -4.5%
Common Shares 115.97
1.16
1.41
1.41
1.42
growth rate -99.0% 21.2% 0.1% 0.6%
Cash Flow Statement Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Capital Expenditures 6.78
3.78
2.92
4.01
4.01
growth rate -44.3% -22.7% 37.3% 0.1%
Cash Dividends
growth rate
Cash From OA 4.50
-18.89
159.99
33.07
-4.30
growth rate -100.0% 100.0% -79.3% -100.0%
Sale Purchase of Stock
growth rate
FCF -2.28
-22.67
157.07
29.06
-8.31
growth rate 0.0% 100.0% -81.5% -100.0%
Income Statement Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Sales 54.85
13.08
21.55
57.76
25.80
growth rate -76.2% 64.8% 168.0% -55.3%
Op.Income 1.47
-44.52
-37.90
-3.70
-43.43
growth rate -100.0% 0.0% 0.0% 0.0%
IBT 4.50
-42.97
-35.97
-1.27
-40.57
growth rate -100.0% 0.0% 0.0% 0.0%
Net Income 4.50
-42.91
-35.93
-1.55
-40.60
growth rate -100.0% 0.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 54.85
-28.40
-19.97
12.48
-26.56
growth rate -100.0% 0.0% 100.0% -100.0%
R&D -38.33
-41.48
-41.52
-45.29
-52.36
growth rate 0.0% 0.0% 0.0% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (52.56)

YOY Growth Grade:

F (12.51)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -15.31 -12.62 -8.88
EPS / Growth 0.0% -0.90 -17.9%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 24.4%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 8.5% 8.5%
Future PE 0.00 0.01 5.64
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.